[3]Jacot W, Im SA, Loi S, et al. Exploratory biomarker analysis of Trastuzumab deruxtecan (TDXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03). 2024 SABCS. PS8-03. [...
在当前的学术文献中,HER2低表达乳腺癌通常被定义为HER2 IHC 1+或IHC 2+,但通过FISH检测未显示基因扩增的浸润性乳腺癌。这类乳腺癌在临床特点、组织形态和分子特性上表现出显著的异质性。 1.1 HER2低表达乳腺癌的临床病理特征 根据Schettini等人的回...
在仅纳入转移性HER2+乳腺癌患者的第一项T-DXd研究(DESTINY-Breast01)中,T-DXd在既往接受过大量治疗的患者队列(既往接受过的治疗中位数为6线,包括T-DM1)中显示出显著疗效,ORR为60.9%,中位PFS为16.4个月,中位OS为28.4个月。该试验以及其他I期和II期试验中观察到的有意义的活性最终推动了DESTINY-Breast03试验,...
[8]Wong Y,Raghavendra AS,Hatzis C,et al.Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2(HER2)Positive Breast Cancers Treated with HER2-Targeted Therapy.Oncologist.2019 Mar;24(3):313-318. [9]Yardley DA,Tripathy D,Brufsky AM,et al.Long-term survivor characteristics ...
[5]Filho OM, Viale G, Stein S, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 2021;11(10): 2474....
[21]Filho OM, Viale G, Stein S, et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021;11(10):2474-2487. ...
of several HER2-targeted agents, including monoclonal antibodies, tyrosine-kinase inhibitors and antibody–drug conjugates, has increased cure rates in patients with early stage HER2-positive (HER2+) breast cancer and substantially improved survival for patients with advanced-stage HER2+ breast cancer. ...
PATIENTS AND METHODS: Patients with stage II to III HER2-positive breast cancer underwent tumor biopsy followed by random assignment to paclitaxel plus trastuzumab alone (TH) or with the addition of lapatinib (THL) for 16 weeks before surgery. An investigational arm of paclitaxel plus lapatinib (...
[1]Nader-Marta G,Martins-Branco D,de Azambuja E.How we treat patients with metastatic HER2-positive breast cancer.ESMO Open.2022 Feb;7(1):100343. [2]Prat A,Guarneri V,ParéL,et al.A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer:a retr...
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives Article 08 January 2024 HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now Article Open access 20 May 2021 Main The discovery of the human epidermal growth ...